Iwabuchi Erina, Miki Yasuhiro, Sasano Hironobu
Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science (IRIDes), Tohoku University, Sendai, Japan.
Acta Histochem Cytochem. 2021 Dec 24;54(6):177-183. doi: 10.1267/ahc.21-00084. Epub 2021 Nov 18.
The therapeutic strategy is determined by protein expression using immunohistochemistry of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) in formalin-fixed paraffin-embedded (FFPE) breast cancer tissues. However, few proteins function independently, and many of them functions due to protein-protein interactions (PPIs) with other proteins. Therefore, it is important to focus on PPIs. This review summarizes the PPIs of ER and HER2 in breast cancer, especially those using a proximity ligation assay that can visualize PPIs in FFPE tissues. In particular, assessing the interaction of CEACAM6 with HER2 may serve as a surrogate marker for the efficacy of trastuzumab in patients with breast cancer. Therefore, in this review, the technique used to detect the interaction of CEACAM6 and HER2 in routinely processed pathological specimens will be applied to the clinical practice of drug selection. We showed the possibility as a novel pathological examination method using PPIs.
治疗策略是通过对福尔马林固定石蜡包埋（FFPE）乳腺癌组织进行雌激素受体（ER）、孕激素受体和人表皮生长因子受体2（HER2）的免疫组织化学检测来确定蛋白质表达情况。然而，很少有蛋白质能独立发挥作用，它们中的许多是通过与其他蛋白质的蛋白质-蛋白质相互作用（PPI）来发挥功能的。因此，关注PPI很重要。本综述总结了乳腺癌中ER和HER2的PPI，特别是那些使用邻近连接分析法的PPI，该方法可以在FFPE组织中可视化PPI。特别是，评估癌胚抗原相关细胞黏附分子6（CEACAM6）与HER2的相互作用可能作为乳腺癌患者曲妥珠单抗疗效的替代标志物。因此，在本综述中，用于检测常规处理病理标本中CEACAM6与HER2相互作用的技术将应用于药物选择的临床实践。我们展示了作为一种使用PPI的新型病理检查方法的可能性。
